This enduring education offers national to local faculty discussions from the North East / Mid-Atlantic and South Regions of the U.S. and aims to improve the knowledge and competence of oncologists, advanced practice providers, pathologists, and pharmacists in implementing biomarker testing and effectively using oral SERDs within a framework of multidisciplinary collaboration to improve patient care in a rapidly evolving therapeutic landscape. As a result of this educational curriculum, learners will be better able to: 1. Integrate testing for ESR1 mutations at appropriate times into practice workflows in the treatment of patients with HR-positive, HER2-negative advanced breast cancer; 2. Evaluate the clinical implications of the latest evidence for approved and late-stage emerging novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer; and, 3. Apply multidisciplinary, patient-centered strategies for optimizing treatment outcomes with novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer. Learners have access to downloadable materials for future use in practice.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 27 Trinity Place, Suite 185
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- includes Online course / module
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedAug 20, 2026
-
Last day to claim creditAug 20, 2027 10 months left
-
PRIME Education, Inc. (PRIME®) Precision Supportive Care in the Oral SERDs Era: Mitigating and Managing Toxicities
-
Med Learning Group The Emerging Role of Oral SERDs in Community Care for Frontline HR+/HER2- Metastatic Breast Cancer
-
Clinical Care Options, LLC (dba Decera Clinical Education) Beyond Resistance: Integrating Next-Generation SERDs Into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer
-
Answers in CME Inc. (AiCME) Ocular Safety in Breast Cancer Care: What Eye Clinicians Need to Know About Novel Oral Endocrine Therapies
-
Answers in CME Inc. (AiCME) Beyond the Biomarker: Bridging Patient Voices and Precision Care in HER2-Mutant NSCLC
-
Answers in CME Inc. (AiCME) The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking New Treatment Opportunities with a Familiar Target
